市場調査レポート
商品コード
1362982

iPS細胞(人工多能性幹細胞)の市場規模、シェア、動向分析レポート:派生細胞タイプ別、用途別、最終用途別、地域別、セグメント別予測、2023年~2030年

Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development, Toxicology Research), End-user, By Region, And Segment Forecasts, 2023 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
iPS細胞(人工多能性幹細胞)の市場規模、シェア、動向分析レポート:派生細胞タイプ別、用途別、最終用途別、地域別、セグメント別予測、2023年~2030年
出版日: 2023年09月12日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

iPS細胞(人工多能性幹細胞)市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界のiPS細胞市場規模は2030年までに30億9,000万米ドルに達し、2023年から2030年までのCAGRは10.61%で拡大すると予測されています。

iPS細胞(iPSC)市場は急速に拡大しています。iPS細胞は、白血病、脊髄損傷、心血管疾患、糖尿病などの病気と闘ったり、闘ったりするために身体に不可欠なあらゆる細胞や組織を生成できることが、その利用の主な理由です。

市場拡大を促進するその他の要因としては、研究費の増加、ゲノミクスイニシアチブの増加、個別化治療におけるゲノム工学の応用の急増などが挙げられます。その結果、iPSCの採用が加速し、市場の収益成長につながっています。例えば、2020年10月、Axxam S.p.A.とFUJIFILM Cellular Dynamics, Inc.は、創薬プロセスを推進するための戦略的パートナーシップを発表しました。ターゲット評価、ハイスループットスクリーニング(HTS)、ハイコンテントスクリーニングを可能にする最先端の創薬技術の使用を通じて、このパートナーシップは創薬研究者と科学者にhiPSCベースのアッセイの統合プラットフォームへのアクセスを提供します。

医療開発と研究への投資は近年大幅に拡大しており、この動向は予測期間中、iPS細胞の需要に大きな影響を与えると予測されます。精密医療におけるヒトiPSC細胞株の応用範囲の拡大や、幹細胞治療応用への重点の高まりは、iPS細胞市場の拡大を促す重要な要因になると予測されます。例えば、両社の共同声明によると、2021年3月、サナバイオテクノロジー社は、富士フイルムセルラーダイナミクス社のiPSCプラットフォームを商業的に利用可能な細胞療法の作製に使用する認可を取得しました。細胞療法は、細胞、組織、臓器など、ヒトの生物学を改善、修正、代替することができます。

COVID-19パンデミック時の研究活動の活発化も、iPSCを用いた研究を後押ししました。さらに、SARS CoV-2感染を管理するための新しい治療法や治療法を発見するための科学者の継続的な努力は、研究ツールとしてのiPSCの必要性を高めています。さらに、iPS細胞は、生理学的に同等なオルガノイドや臓器モデルを作ることができるため、ヒトにおけるウイルス感染の病態生理学の研究に利用することができます。そのため、業界の成長を後押ししています。

さらに、iPS細胞に関連する様々な科学的活動に焦点を当てた産業の成長とともに、政府や商業部門が資金を拡大しており、様々な組織を通じて人々の幹細胞に対する認識も高まっています。しかし、細胞の初期化にかかるコストの高さ、倫理的な懸念、時間のかかるプロセスといった課題が、iPS細胞産業の成長を一定の範囲で阻害しています。さらに、効率の低さ、潜在的な腫瘍リスク、不十分なプログラミングも、iPSC市場の拡大を制限する懸念事項です。

iPS細胞市場レポートハイライト

  • 派生細胞タイプ別では、線維芽細胞セグメントが2022年に30.48%の最大シェアを占めました。医療専門家の間で、皮膚問題の潜在的治療法として線維芽細胞への嗜好が高まっていることが、同分野の成長を後押ししています。
  • 用途別では、医薬品開発分野が2022年に49.09%の最大シェアを占めました。慢性疾患の蔓延、座りがちなライフスタイルなどが個別化治療の需要を高めており、iPS細胞の助けを借りて医薬品を開発する製薬・バイオテクノロジー企業の関心の高まりが業界の成長を促進しています。
  • 最終用途別では、製薬・バイオテクノロジー企業が2022年に59.77%の最大シェアを占めました。このセグメントは、iPS細胞を用いて様々な疾患のための様々な幹細胞製品・技術を製造・開発しているため、市場を独占すると予測されています。
  • 2022年には、北米が42.36%と大きなシェアを占める。これは、医薬品研究、毒性試験、疾患モデリングにおいて革新的なシステムや技術の利用が増加していることが主な理由であり、また、この地域では幹細胞治療が受け入れられつつあることも市場を牽引する主な要因となっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
  • 市場動向と展望
  • 市場力学
  • 市場抑制要因分析
  • 事業環境分析

第4章 派生細胞タイプのビジネス分析

  • 世界のiPS細胞市場:派生細胞タイプの変動分析
  • 肝細胞
  • 線維芽細胞
  • ケラチノサイト
  • 羊膜細胞
  • その他

第5章 用途のビジネス分析

  • 世界のiPS細胞市場:用途の変動分析
  • 医薬品開発
  • 組織工学と再生医療
  • 毒物学の研究
  • 疾患モデリング

第6章 エンドユーザーのビジネス分析

  • 世界のiPS細胞市場:エンドユーザーの変動分析
  • 学術・研究機関
  • 製薬・バイオテクノロジー企業
  • その他

第7章 地域のビジネス分析

  • 世界のiPS細胞市場シェア(地域別、2022年および2030年)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業の市場シェア分析、2022年
  • 企業プロファイル・一覧表
    • STEMCELL Technologies Inc.
    • Cellular Engineering Technologies Inc.
    • REPROCELL Inc.
    • Takara Bio, Inc.
    • Axol Bioscience Ltd.
    • Fate Therapeutics, Inc.
    • FUJIFILM Corporation(FUJIFILM Cellular Dynamics, Inc.)
    • Cynata Therapeutics Limited
    • Evotec SE
    • Astellas Pharma Inc.
図表

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 4 Global Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 5 Global Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 6 North America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 7 North America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 8 North America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 9 North America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 10 U.S. Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 14 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 16 Europe Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 20 UK Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 21 UK Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 22 UK Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 25 Germany Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 26 France Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 27 France Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 28 France Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 29 Italy Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 31 Italy Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 32 Spain Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 34 Spain Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 35 Denmark Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 37 Denmark Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 38 Sweden Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 40 Sweden Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 41 Norway Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 43 Norway Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 48 China Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 49 China Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 50 China Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 51 Japan Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 53 Japan Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 54 India Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 55 India Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 56 India Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 57 South Korea Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 59 South Korea Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 60 Australia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 62 Australia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 63 Thailand Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 65 Thailand Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 66 Latin America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 68 Latin America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 70 Brazil Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 72 Brazil Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 73 Mexico Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 75 Mexico Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Induced Pluripotent Stem Cells Market by End-User, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 83 South Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 85 South Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 91 UAE Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Induced Pluripotent Stem Cells Market By End-Use, 2018 - 2030 (USD Million)
  • Table 95 Participant's Overview
  • Table 96 Financial Performance
  • Table 97 Key Companies Undergoing Expansions
  • Table 98 Key Companies Undergoing Acquisitions
  • Table 99 Key Companies Undergoing Collaborations
  • Table 100 Key Companies Launching New Products/Services
  • Table 101 Key Companies Undergoing Partnerships
  • Table 102 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2022 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Global induced pluripotent stem cells market: Derived cell type outlook and key takeaways
  • Fig. 16 Global induced pluripotent stem cells market: Derived cell type movement analysis
  • Fig. 17 Global hepatocytes market, 2018 - 2030 (USD Million)
  • Fig. 18 Global fibroblasts market, 2018 - 2030 (USD Million)
  • Fig. 19 Global keratinocytes market, 2018 - 2030 (USD Million)
  • Fig. 20 Global amniotic cells market, 2018 - 2030 (USD Million)
  • Fig. 21 Global others market, 2018 - 2030 (USD Million)
  • Fig. 22 Global induced pluripotent stem cells market: Application outlook and key takeaways
  • Fig. 23 Global induced pluripotent stem cells market: Application movement analysis
  • Fig. 24 Global drug development market, 2018 - 2030 (USD Million)
  • Fig. 25 Global tissue engineering & regenerative medicine market, 2018 - 2030 (USD Million)
  • Fig. 26 Global neurology market, 2018 - 2030 (USD Million)
  • Fig. 27 Global orthopedics market, 2018 - 2030 (USD Million)
  • Fig. 28 Global oncology market, 2018 - 2030 (USD Million)
  • Fig. 29 Global cardiovascular and myocardial infraction market, 2018 - 2030 (USD Million)
  • Fig. 30 Global diabetes market, 2018 - 2030 (USD Million)
  • Fig. 31 Global others market, 2018 - 2030 (USD Million)
  • Fig. 32 Global toxicology research market, 2018 - 2030 (USD Million)
  • Fig. 33 Global disease modeling market, 2018 - 2030 (USD Million)
  • Fig. 34 Global induced pluripotent stem cells market: End-use outlook and key takeaways
  • Fig. 35 Global induced pluripotent stem cells market: End-use movement analysis
  • Fig. 36 Global academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 37 Global pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
  • Fig. 38 Global induced pluripotent stem cells market: Regional outlook and key takeaways
  • Fig. 39 North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 44 Europe induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Germany key country dynamics
  • Fig. 46 Germany induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 France key country dynamics
  • Fig. 48 France induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Asia-Pacific induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 India key country dynamics
  • Fig. 65 India induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea key country dynamics
  • Fig. 67 South Korea induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Australia key country dynamics
  • Fig. 71 Australia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 MEA induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Market participant categorization
  • Fig. 91 induced pluripotent stem cells market share analysis, 2022
  • Fig. 92 Strategy framework
目次
Product Code: GVR-4-68040-116-1

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.09 billion by 2030 and is expected to expand at a CAGR of 10.61% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report highlights

  • By derived cell type, the fibroblasts segment accounted for the largest share of 30.48% in 2022. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
  • By application, the drug developmentsegment accounted for the largest share of 49.09% in 2022. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
  • By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.77% in 2022. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
  • North America held the larger share of 42.36% in 2022. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Information analysis
    • 1.2.2. Market formulation & data visualization
    • 1.2.3. Data validation & publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Europe Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Increase in research and development activities in stem cells therapies
    • 3.3.2. Surge in adoption of personalized medicine
  • 3.4. Market Restraint Analysis
    • 3.4.1. Lack of awareness regarding stem cell therapies
    • 3.4.2. High cost of treatment
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Derived Cell Type Business Analysis

  • 4.1. Global induced pluripotent stem cells market: Derived Cell Type Movement Analysis
  • 4.2. Hepatocytes
    • 4.2.1. Hepatocytes Market, 2018 - 2030 (USD Million)
  • 4.3. Fibroblasts
    • 4.3.1. Fibroblasts Market, 2018 - 2030 (USD Million)
  • 4.4. Keratinocytes
    • 4.4.1. Keratinocytes Market, 2018 - 2030 (USD Million)
  • 4.5. Amniotic Cells
    • 4.5.1. Amniotic Cells Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Global induced pluripotent stem cells market: Application Movement Analysis
  • 5.2. Drug Development
    • 5.2.1. Drug Development Market, 2018 - 2030 (USD Million)
  • 5.3. Tissue Engineering & Regenerative Medicine
    • 5.3.1. Tissue Engineering & Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 5.3.2. Neurology
      • 5.3.2.1. Neurology Market, 2018 - 2030 (USD Million)
    • 5.3.3. Orthopedics
      • 5.3.3.1. Orthopedics Market, 2018 - 2030 (USD Million)
    • 5.3.4. Oncology
      • 5.3.4.1. Oncology Market, 2018 - 2030 (USD Million)
    • 5.3.5. Cardiovascular and Myocardial Infraction
      • 5.3.5.1. Cardiovascular and Myocardial Infraction Market, 2018 - 2030 (USD Million)
    • 5.3.6. Diabetes
      • 5.3.6.1. Diabetes Market, 2018 - 2030 (USD Million)
    • 5.3.7. Others
      • 5.3.7.1. Others Market, 2018 - 2030 (USD Million)
  • 5.4. Toxicology Research
    • 5.4.1. Toxicology Research Market, 2018 - 2030 (USD Million)
  • 5.5. Disease Modeling
    • 5.5.1. Disease Modeling Market, 2018 - 2030 (USD Million)

Chapter 6. End-User Business Analysis

  • 6.1. Global induced pluripotent stem cells market: End-User Movement Analysis
  • 6.2. Academic & Research Institutes
    • 6.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 6.3. Pharmaceutical & Biotechnology Companies
    • 6.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Global Induced Pluripotent Stem Cells Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Target Disease Prevalence
      • 7.2.2.5. U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Target Disease Prevalence
      • 7.2.3.5. Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Induced Pluripotent Stem Cells Market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Target Disease Prevalence
      • 7.3.2.5. Germany induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Target Disease Prevalence
      • 7.3.3.5. UK induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Target Disease Prevalence
      • 7.3.4.5. France induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Target Disease Prevalence
      • 7.3.5.5. Italy induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Target Disease Prevalence
      • 7.3.6.5. Spain induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Target Disease Prevalence
      • 7.3.7.5. Denmark induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Target Disease Prevalence
      • 7.3.8.5. Sweden induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Target Disease Prevalence
      • 7.3.9.5. Norway induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Target Disease Prevalence
      • 7.4.2.5. Japan induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Target Disease Prevalence
      • 7.4.3.5. China induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Target Disease Prevalence
      • 7.4.4.5. India induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Target Disease Prevalence
      • 7.4.5.5. South Korea induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Target Disease Prevalence
      • 7.4.6.5. Australia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Target Disease Prevalence
      • 7.4.7.5. Thailand induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Target Disease Prevalence
      • 7.5.2.5. Brazil induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Target Disease Prevalence
      • 7.5.3.5. Mexico induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Target Disease Prevalence
      • 7.5.4.5. Argentina induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Target Disease Prevalence
      • 7.6.2.5. South Africa induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Target Disease Prevalence
      • 7.6.3.5. Saudi Arabia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Target Disease Prevalence
      • 7.6.4.5. UAE induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Target Disease Prevalence
      • 7.6.5.5. Kuwait induced pluripotent stem cells market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2022
  • 8.4. Company Profiles/Listing
    • 8.4.1. STEMCELL Technologies Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Cellular Engineering Technologies Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. REPROCELL Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Takara Bio, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Axol Bioscience Ltd.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Fate Therapeutics, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. FUJIFILM Corporation (FUJIFILM Cellular Dynamics, Inc.)
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Cynata Therapeutics Limited
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Evotec SE
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Astellas Pharma Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives